NDA 022581 · Fresenius Medcl Care
Phoslyra
Calcium Acetate · Oral
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Apr 18, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
8 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 18, 2011 Original approval · Type 3 - New Dosage Form OrphanSummary ReviewLetterLabel
1 products under this application
- PHOSLYRA · CALCIUM ACETATE 667MG/5ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Phoslyra" as an intervention, any sponsor and status, largest first.
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisPivotal-lookingCompleted
Keryx BiopharmaceuticalsIndustry
NCT01191255 · 441 participants · Start Oct 2010 · Primary completion Jan 2013
Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo · For: Hyperphosphatemia; Kidney Failure
Sites: Tempe, Arizona; Los Angeles, California; Riverside, California · 56 sites in all
- Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage VPivotal-lookingActive, not recruiting
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT03565913 · 269 participants · Start Jan 22, 2017 · Primary completion Dec 1, 2026
Drug: EffCaMgCit · For: CKD Stage 5
Sites: Dallas, Texas
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyPivotal-lookingCompleted
ArdelyxIndustry
NCT03824587 · 236 participants · Start Feb 28, 2019 · Primary completion Jul 17, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Beverly Hills, California · 48 sites in all
- CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis PatientsPivotal-lookingCompleted
Nabi BiopharmaceuticalsIndustry
NCT00211939 · 203 participants · Start Jan 2005 · Primary completion Dec 2006
Drug: calcium acetate; sevelamer and 1 more · For: Calcinosis; Arteriosclerosis; Hyperparathyroidism, Secondary
Sites: San Antonio, Texas
- Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis PatientsPivotal-lookingCompleted
Chugai Pharma TaiwanIndustry
NCT01755078 · 166 participants · Start Jun 2007 · Primary completion Jun 2009
Drug: Sevelamer HCl; Calcium-based phosphate binder · For: Hemodialysis; Hyperphosphatemia; Cardiovascular Events
- A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKDPivotal-lookingCompleted
Denver Nephrologists, P.C.Academic, hospital or other
NCT00785629 · 148 participants · Start Feb 2009 · Primary completion Jul 2011
Drug: Calcium acetate; Lanthanum Carbonate and 2 more · For: Chronic Kidney Disease
Sites: Denver, Colorado
- Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal DialysisPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00196755 · 138 participants · Start Dec 2004 · Primary completion Mar 2006
Drug: Sevelamer Hydrochloride (Renagel®); Calcium acetate (PhosLo® ) · For: Peritoneal Dialysis; Chronic Kidney Disease
Sites: Leuven, Belgium; Århus N, Denmark; Fredericia, Denmark · 17 sites in all
- Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus RestrictionPivotal-lookingStatus unknown
Salem Veterans Affairs Medical CenterFederal agency
NCT01357317 · 120 participants (planned) · Start Jun 2011 · Primary completion Oct 2013
Drug: Phosphorus binder · For: Chronic Kidney Disease
Sites: Salem, Virginia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Fresenius Medcl Care
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.